<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00147875</url>
  </required_header>
  <id_info>
    <org_study_id>PVAG elderly</org_study_id>
    <nct_id>NCT00147875</nct_id>
  </id_info>
  <brief_title>Study of Prednisone, Vinblastine, Doxorubicin, and Gemcitabine in Elderly Patients With Advanced Stages Hodgkin's Lymphoma</brief_title>
  <official_title>PVAG - Phase I/II Dose Finding Trial in Elderly Patients (&gt; 60 Years) With Advanced Stages Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cologne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Hodgkin's Lymphoma Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cologne</source>
  <brief_summary>
    <textblock>
      The objectives of this study are to assess the feasibility and efficacy of a combination
      chemotherapy (PVAG) in elderly patients with advanced stages Hodgkin's lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gemcitabine shows promising activity in patients with relapsed lymphoma either administered
      as single agent or in combination with other cytotoxic agents. No trial to date evaluated its
      role in patients with primary Hodgkin's lymphoma. We therefore developed a three-weekly
      regimen based on the standard ABVD regimen.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I: Dose-limiting toxicities and dose reductions</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II: Treatment administration and complete response rate</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicities</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Supportive care (RBCT need, antibiotic need)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early progression rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <enrollment type="Actual">60</enrollment>
  <condition>Hodgkin's Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinblastine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin (Adriamycin)</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hodgkin's lymphoma (histologically proven)

          -  Clinical stage IIB (with risk factors bulky mediastinal mass and/or extranodal
             involvement), III, or IV

          -  No prior antitumor therapy

          -  Age 60 to 75 years

          -  WHO performance status 0-2

          -  Normal pulmonary function

          -  Written informed consent

        Exclusion Criteria:

          -  The following histologies are excluded: lymphocyte predominant HD

          -  Leukocytes &lt; 2,500/microL

          -  Platelets &lt; 100,000/microL
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Engert</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cologne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Cologne</name>
      <address>
        <city>Cologne</city>
        <state>NRW</state>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2005</study_first_submitted>
  <study_first_submitted_qc>September 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2005</study_first_posted>
  <last_update_submitted>September 4, 2009</last_update_submitted>
  <last_update_submitted_qc>September 4, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 7, 2009</last_update_posted>
  <keyword>Lymphoma</keyword>
  <keyword>Gemcitabine</keyword>
  <keyword>Advanced stages Hodgkin's lymphoma</keyword>
  <keyword>Elderly</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

